Protocol: Pentoxifylline optimal dose finding trial in preterm neonates with suspected late onset sepsis (PTX-trial)

Serife Kurul, H Rob Taal, Robert B Flint, Jan Mazela, Irwin K M Reiss, Karel Allegaert, Sinno H P Simons, Serife Kurul, H Rob Taal, Robert B Flint, Jan Mazela, Irwin K M Reiss, Karel Allegaert, Sinno H P Simons

Abstract

Background: Late onset sepsis is a leading cause of death and morbidity in preterm infants. Despite optimal antibiotic treatment, sepsis related mortality and morbidity is still high. Pentoxifylline (PTX) is a methylxanthine with promising immunomodulatory properties, which can be used as an additional therapy next to antibiotics in preterm infants. PTX is increasingly used off-label in neonatal intensive care units, however up till now no dose finding study has been done for PTX in this specific population. The aim of this study (PTX-trial) is to determine the optimal dose of PTX in preterm infants (gestational age < 30 weeks) with (suspected) late onset sepsis. Dose finding in this particular population is unique, since for most drugs used in neonates the optimal dosage has not been investigated in phase II dose-seeking studies.

Methods: The PTX-trial is a prospective open label sequential dose-optimization study with an adapted continual reassessment method. An up-and-down dose-response design will be used, with dose step-up and step-down titration after every 3 patients. The PTX starting dosage will be 30 mg/kg/day in 6 hours as described in most previous neonatal studies. Efficacy is defined by means of biochemical and clinical parameters. Toxicity in these vulnerable patients is unwarranted. The optimal dose is defined as the ED75 (i.e., clinically and chemically effective dose for 75% of patients) in preterm neonates with late onset sepsis. We plan to include 30 neonates to determine the optimal dose using this study design. Subsequently, the optimal dose will be validated in 10 additional preterm neonates. In parallel, pharmacokinetics of PTX and its metabolites will be described as well as longitudinal evaluation of metabolomics and proteomics.

Discussion: The study has been approved by the Regional Medical Ethics Board of Erasmus Medical Center University Rotterdam (MEC 2019-0477) and registered at Clinicaltrials.gov (NCT04152980). Results of the main trial and each of the secondary endpoints will be submitted for publications in peer-reviewed journals.

Trial registration: Clinicaltrials.gov, NCT04152980 , Registered November 6th, 2019.

Keywords: Neonatal intensive & critical care; Neonatology; Paediatric infectious disease & immunization.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
PTX-trial study flowchart. NEC, necrotizing enterocolitis; AUC, area under the curve; AB, antibiotics
Fig. 2
Fig. 2
PTX-trial experimental dose-steps of tested dosages
Fig. 3
Fig. 3
PTX-trial, Clinical decision rule for dose adjustment

References

    1. Lawn JE, Wilczynska-Ketende K, Cousens SN. Estimating the causes of 4 million neonatal deaths in the year 2000. Int J Epidemiol. 2006;35(3):706–718.
    1. Stoll BJ, Hansen N, editors. Infections in VLBW infants: studies from the NICHD Neonatal Research Network. Seminars in perinatology; 2003: Elsevier.
    1. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002;110(2):285–291.
    1. Shane AL, Sánchez PJ, Stoll BJ. Neonatal sepsis. Lancet. 2017;390(10104):1770–1780.
    1. Pammi M, Weisman LE. Late-onset sepsis in preterm infants: update on strategies for therapy and prevention. Exp Rev Anti Infect Ther. 2015;13(4):487–504.
    1. Schultz C, Reiss I, Bucsky P, Göpel W, Gembruch U, Ziesenitz S, et al. Maturational changes of lymphocyte surface antigens in human blood: comparison between fetuses, neonates and adults. Neonatology. 2000;78(2):77–82.
    1. Strunk T, Temming P, Gembruch U, Reiss I, Bucsky P, Schultz C. Differential maturation of the innate immune response in human fetuses. Pediatr Res. 2004;56(2):219.
    1. Kurul S, Allegaert K, Flint RB, Taal HR. How can a drug to treat claudication in adults save preterm newborns? Eur J Pediatr. 2020;179(8):1331–4.
    1. Neuner P, Klosner G, Schauer E, Pourmojib M, Macheiner W, Grünwald C, et al. Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology. 1994;83(2):262.
    1. Mandell GL. Cytokines, phagocytes, and pentoxifylline. J Cardiovasc Pharmacol. 1995;25:S20–S22.
    1. Windmeier C, Gressner AM. Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. Gen Pharmacol Vasc Syst. 1997;29(2):181–196.
    1. Schröer RH. Antithrombotic potential of pentoxifylline a hemorheologically active drug. Angiology. 1985;36(6):387–398.
    1. Haque KN, Pammi M. Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates. Cochrane Database Syst Rev. 2011;(10):CD004205:1–22.
    1. Harris E, Schulzke SM, Patole SK. Pentoxifylline in preterm neonates. Pediatr Drugs. 2010;12(5):301–311.
    1. Pammi M, Haque KN. Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates. Cochrane Database Syst Rev. 2015;(3):CD004205.1–33.
    1. Shabaan AE, Nasef N, Shouman B, Nour I, Mesbah A, Abdel-Hady H. Pentoxifylline therapy for late-onset sepsis in preterm infants: a randomized controlled trial. Pediatr Infect Dis J. 2015;34(6):e143–e1e8.
    1. Allegaert K, Van De Velde M, van den Anker J. Neonatal clinical pharmacology. Pediatr Anesth. 2014;24(1):30–38.
    1. Völler S, Flint RB, Andriessen P, Allegaert K, Zimmermann LJI, Liem KD, et al. Rapidly maturing fentanyl clearance in preterm neonates. Arch Dis Childhood Fetal Neonatal Edn. 2019;104(6):F598–F603.
    1. Salman S, Hibbert J, Page-Sharp M, Manning L, Simmer K, Doherty DA, et al. Effects of maturation and size on population pharmacokinetics of pentoxifylline and its metabolites in very preterm infants with suspected late-onset sepsis or necrotizing enterocolitis: a pilot study incorporating clinical outcomes. Br J Clin Pharmacol. 2019;85(1):147–159.
    1. Kurul Ş, Simons SHP, Ramakers CRB, De Rijke YB, Kornelisse RF, Reiss IKM, et al. Association of inflammatory biomarkers with subsequent clinical course in suspected late onset sepsis in preterm neonates. Crit Care. 2021;25(1):12.
    1. Boskabadi H, Maamouri G, Tavakol Afshari J, Mafinejad S, Hosseini G, Mostafavi-Toroghi H, et al. Evaluation of serum interleukins-6, 8 and 10 levels as diagnostic markers of neonatal infection and possibility of mortality. Iran J Basic Med Sci. 2013;16(12):1232–1237.
    1. Wheeler GM, Mander AP, Bedding A, Brock K, Cornelius V, Grieve AP, et al. How to design a dose-finding study using the continual reassessment method. BMC Med Res Methodol. 2019;19(1):1–15.
    1. Jones S, Carley S, Harrison M. An introduction to power and sample size estimation. Emerg Med J. 2003;20(5):453.
    1. Lauterbach R, Pawlik D, Tomaszczyk B, Cholewa B. Pentoxifylline treatment of sepsis of premature infants: preliminary clinical observations. Eur J Pediatr. 1994;153(9):672–674.
    1. Lauterbach R, Pawlik D, Kowalczyk D, Ksycinski W, Helwich E, Zembala M. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial. Crit Care Med. 1999;27(4):807–814.
    1. Adel M, Awad HAS, Abdel-Naim AB, Al-Azizi MMM. Effects of pentoxifylline on coagulation profile and disseminated intravascular coagulation incidence in Egyptian septic neonates. J Clin Pharm Ther. 2010;35(3):257–265.
    1. Lauterbach R, Szymura-Oleksiak J. Nebulized pentoxifylline in successful treatment of five premature neonates with bronchopulmonary dysplasia. Eur J Pediatr. 1999;158(7):607.
    1. Lauterbach R, Zembala M. Pentoxifylline reduces plasma tumour necrosis factor-alpha concentration in premature infants with sepsis. Eur J Pediatr. 1996;155(5):404–409.
    1. Akdag A, Dilmen U, Haque K, Dilli D, Erdeve O, Goekmen T. Role of pentoxifylline and/or IgM-enriched intravenous immunoglobulin in the management of neonatal sepsis. Am J Perinatol. 2014;31(10):905–912.
    1. Selim K, Huseyin C, Ibrahim KH, Hasan BU, Kazim U, Huseyin K. Effect of pentoxifylline on tumor necrosis factor-alpha and interleukin-6 levels in neonatal sepsis. Med J Malays. 2004;59(3):391–394.
    1. Ridings PC, Windsor ACJ, Sugerman HJ, Kennedy E, Sholley MM, Blocher CR, et al. Beneficial cardiopulmonary effects of pentoxifylline in experimental sepsis are lost once septic shock is established. Arch Surg. 1994;129(11):1144–1152.
    1. Du W, Lehr VT, Lieh-Lai M, Koo W, Ward RM, Rieder MJ, et al. An algorithm to detect adverse drug reactions in the neonatal intensive care unit. J Clin Pharmacol. 2013;53(1):87–95.
    1. Salaets T, Turner MA, Short M, Ward RM, Hokuto I, Ariagno RL, et al. Development of a neonatal adverse event severity scale through a Delphi consensus approach. Arch Dis Childhood. 2019;104(12):1167–1173.
    1. Dixon WJ. The up-and-down method for small samples. J Am Stat Assoc. 1965;60(312):967–978.
    1. Embleton ND, Turnbull E, Turner S, Berrington JE. Successful blood salvaging from preterm infants: maximizing opportunities, minimizing interventions. Acta Paediatr. 2013;102(11):e527–e529.
    1. Keizer RJ, Karlsson MO, Hooker A. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT: Pharmacometrics Syst Pharmacol. 2013;2(6):1–9.
    1. Lindbom L, Pihlgren P, Jonsson N. PsN-Toolkit—a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Prog Biomed. 2005;79(3):241–257.
    1. Stewart CJ, Nelson A, Treumann A, Skeath T, Cummings SP, Embleton ND, et al. Metabolomic and proteomic analysis of serum from preterm infants with necrotising entercolitis and late-onset sepsis. Pediatr Res. 2016;79(3):425–431.
    1. Strunk T, Inder T, Wang X, Burgner D, Mallard C, Levy O. Infection-induced inflammation and cerebral injury in preterm infants. Lancet Infect Dis. 2014;14(8):751–762.
    1. Wynn J, Cornell TT, Wong HR, Shanley TP, Wheeler DS. The host response to sepsis and developmental impact. Pediatrics. 2010;125(5):1031–1041.
    1. Schüller SS, Wisgrill L, Herndl E, Spittler A, Förster-Waldl E, Sadeghi K, et al. Pentoxifylline modulates LPS-induced hyperinflammation in monocytes of preterm infants in vitro. Pediatr Res. 2017;82(2):215.
    1. Schrier L, Hadjipanayis A, Stiris T, Ross-Russell RI, Valiulis A, Turner MA, et al. Off-label use of medicines in neonates, infants, children, and adolescents: a joint policy statement by the European Academy of Paediatrics and the European society for Developmental Perinatal and Pediatric Pharmacology. Eur J Pediatr. 2020;179(5):839–47.
    1. Turner MA. Neonatal drug development. Early Hum Dev. 2011;87(11):763–768.
    1. Turner MA, Lewis S, Hawcutt DB, Field D. Prioritising neonatal medicines research: UK Medicines for Children Research Network scoping survey. BMC Pediatr. 2009;9(1):50.
    1. Jardine L, Davies MW, Faoagali J. Incubation time required for neonatal blood cultures to become positive. J Paediatr Child Health. 2006;42(12):797–802.
    1. van der Zanden TM, de Wildt SN, Liem Y, Offringa M, de Hoog M, Dutch Paediatric Pharmacotherapy Expertise Network N Developing a paediatric drug formulary for the Netherlands. Arch Dis Child. 2017;102(4):357–361.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する